Ovid Therapeutics (OVID) Cash & Current Investments (2016 - 2026)

Ovid Therapeutics' Cash & Current Investments history runs 11 years deep, the most recent figure standing at $155.5 million for Q1 2026.

• Quarterly Cash & Current Investments rose 281.32% year-over-year to $155.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $155.5 million (up 281.32% YoY) and the FY2025 annual result came in at $69.6 million, up 32.5% from the prior year.
• Cash & Current Investments was $155.5 million for Q1 2026 at Ovid Therapeutics, up from $69.6 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $168.6 million in Q1 2022 and bottomed at $25.5 million in Q3 2025.
• A 5-year average of $94.0 million and a median of $88.9 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2025 — Cash & Current Investments plunged 58.19% — and 2026, when it soared 281.32%.
• Ovid Therapeutics' Cash & Current Investments stood at $126.1 million in 2022, then retreated by 18.25% to $103.1 million in 2023, then tumbled by 49.04% to $52.6 million in 2024, then soared by 32.5% to $69.6 million in 2025, then surged by 123.34% to $155.5 million in 2026.
• Business Quant data shows OVID's Cash & Current Investments at $155.5 million in Q1 2026, $69.6 million in Q4 2025, and $25.5 million in Q3 2025.